Since activating mutations in core components of the Wnt/beta-catenin pathway are rarely found in breast cancer, we hypothesize the existence of a complex network of positive and negative regulatory mechanisms that establish precise Wnt/beta-catenin signaling levels most beneficial for a preferred balance of tumor growth, survival, and overall progression. The gene discussed is CTNNB1; the disease is neoplasm.